| Year | Panel |
Screening items# |
|||
|---|---|---|---|---|---|
| HPA | CH | CAH | G6PDd | ||
| May | 100 | 80 | 100 | 100 | |
| 2015 | August | 100 | 80 | 100 | 100 |
| October | 100 | 100 | 100 | 100 | |
| May | 100 | 100 | 100 | 100 | |
| 2016 | August | 80 | 100 | 100 | 100 |
| October | 100 | 100 | 100 | 100 | |
| May | 100 | 100 | 100 | 100 | |
| 2017 | August | 100 | 100 | 100 | 100 |
| October | 100 | 100 | 100 | 100 | |
| May | 100 | 100 | 100 | 100 | |
| 2018 | August | 100 | 100 | 100 | 100 |
| October | 100 | 100 | 100 | 100 | |
| May | 100 | 100 | 100 | 100 | |
| 2019 | August | 100 | 100 | 100 | 100 |
| October | 100 | 100 | 100 | 100 | |
#100 points are given when all five replicates are classified correctly; 80 points or more is considered acceptable performance and less than 80 points is unacceptable.
HPA, hyperphenylalaninemia; CH, congenital hypothyroidism; CAH, congenital adrenocortical hyperplasia; G6PDd, glucose-6-phosphate dehydrogenase deficiency.